Long-Term Persistence and Effectiveness of Risankizumab in Multi-Refractory Psoriatic Arthritis: A 16-Center Real-World Registry (SKYREAL) (ACR Convergence 2026) - Sep 8, 2026 - Abstract #363; Pres time: Nov 8, 2026; 10:30 AM - 12:30 PM; Location: WB1&2; In Person; "In the largest real-world rheumatology cohort of risankizumab in PsA to date, the drug showed high long-term persistence and robust, sustained efficacy in heavily pretreated patients, with a favorable safety profile. Baseline articular disease activity (DAPSA) was the principal predictor of early discontinuation, supporting closer monitoring of high-activity patients during the first year. Continuous variables: mean ± SD; categorical: n (%)."
Clinical • Real-world • Real-world evidence • Cardiovascular • Immunology • Infectious Disease • Inflammatory Arthritis • Psoriatic Arthritis • Rheumatology • Seronegative Spondyloarthropathies • Urticaria • CRP • IL17A
|
|
Maria Vanesa Hernández Hernández 1; Antonio Álvarez de Cienfuegos 2; Isabel Peinado Ruiz 3; Luis Gómez-Lechón Quirós 4; Vicente Aldasoro 5; Maria Laino 6; Marilo Toledo 7; Blanca Viejo 7; Alba Belmonte-Mora 8; Enrique Raya 9; BEATRIZ JOVEN 10; Cristina Valero-Martínez 11; Cristina Campos Fernández 12; Jesús Cerdeña Corrales 13; Isabel Martinez Cordellat 12; Cristina Martinez Gonzalez 14; Hiurma Sanchez-Perez 14; Carmen Carrasco Cubero 15; Laura Nuño 16; Diana Peiteado 17; Pablo Rodriguez-Merlos 18; Ana Belen Azuaga 19; Julio Ramírez 20; Enrique González Dávila 21; and Federico Diaz-Gonzalez 14
|